Cromolyn compositions and methods thereof
Methods of delivering cromolyn to a patient in need thereof, methods of treating amyloid-associated conditions and inflammatory or allergic lung diseases, and packs and kits comprising cromolyn are described.
1. A capsule containing a powder composition comprising about 16.1 mg to about 19.9 mg of a pharmaceutically acceptable salt or ester of cromolyn in the form of a powder comprising particles of the pharmaceutically acceptable salt or ester of cromolyn, the majority of particles having a diameter of about 2 to about 5 microns, wherein said composition is capable of being delivered using a device that deposits (a) at least 3.0 mg and (b) at least 20% by weight of the administered amount of pharmaceutically acceptable salt or ester of cromolyn to Stage 4 and higher of a Next Generation Pharmaceutical Impactor (NGI) cascade impactor device at a flow rate of 60-80 Imin.
2. The capsule of claim 1 , wherein the composition comprises about 17.1 mg of the pharmaceutically acceptable salt or ester of cromolyn.
3. The capsule of claim 1 , wherein the device is selected from the group consisting of a dry powder inhaler (DPI) device, a metered dose inhaler (MDI) device, and a dry powder nebulizer (DPN) device.
4. The capsule of claim 1 , wherein the device is a single-dose inhalation device that delivers the powder as an aerosol.
5. The capsule of claim 1 , wherein the composition further comprises one or more pharmaceutically acceptable excipients.
6. The capsule of claim 1 , wherein the composition comprises about 50% to about 60% (w/w) of the pharmaceutically acceptable salt or ester of cromolyn and about 40% to about 50% of one or more excipients.
7. The capsule of claim 6 , wherein the excipient is selected from the group consisting of a monosaccharide, a disaccharide, an oligosaccharide, a polysaccharide, a polyalcohol, and lactose.
8. The capsule of claim 6 , wherein the excipient is selected from the group consisting of lactose, mannitol, and sorbitol.
9. The capsule of claim 1 , wherein the composition does not comprise an active ingredient other than the pharmaceutically acceptable salt or ester of cromolyn.
10. The capsule of claim 1 , wherein the composition does not comprise a non-steroidal anti-inflammatory drug.
11. The capsule of claim 1 , wherein the composition does not comprise ibuprofen.
12. A method of delivering cromolyn to a patient in need thereof, comprising administering the powder composition contained within the capsule of claim 1 to the patient via oral inhalation, wherein the particles of said powder have a mass median particle size (D50) of less than about 5 microns; and wherein the composition is administered using a device that deposits about 4 mg to about 5 mg of cromolyn to the secondary bronchi of the patient at a flow rate of 60-80 L/min.
13. The method of claim 12 , wherein the method comprises administering about 17.1 mg of the pharmaceutically acceptable salt or ester of cromolyn, and wherein said composition optionally comprises one or more pharmaceutically acceptable excipients.
14. The method of claim 12 , wherein the device is selected from the group consisting of a dry powder inhaler (DPI) device, a metered dose inhaler (MDI) device, and a dry powder nebulizer (DPN) device.
15. The method of claim 12 , wherein administering comprises suspending the powder into an inhaled gas stream.
16. The method of claim 12 , wherein administering comprises vibrating the powder at high frequency.
17. The method of claim 16 , wherein the frequency is about 10 kHz to about 50 kHz.
18. The method of claim 14 , wherein the device is a dry powder inhaler comprising a chamber comprising a piezoelectric vibrator or an ultrasonic vibrator for deaggregating a dry powder and an air flow passageway in which the deaggregated powder is picked up and carried for oral inhalation by a patient.
19. The method of claim 14 , wherein the dry powder inhaler device is a single-dose device consisting of a container, a valve, and a mouthpiece.
20. The method of claim 14 , wherein the device is a dry powder inhaler device.
21. The method of claim 12 , wherein the powder comprises about 0.1% to about 80% by weight of an excipient.
22. The method of claim 12 , wherein the powder comprises about 40% to about 80% by weight of an excipient.
23. The method of claim 12 , wherein the powder comprises about 40% to about 45% by weight of an excipient.
24. The method of claim 21 , wherein the excipient is selected from the group consisting of a monosaccharide, a disaccharide, an oligosaccharide, a polysaccharide, and a polyalcohol.
25. The method of claim 21 , wherein the excipient is selected from the group consisting of lactose, mannitol, and sorbitol.
26. The method of claim 25 , wherein excipient further comprises a hydrophobic salt.
27. The method of claim 26 , wherein the hydrophobic salt comprises a stearate.
28. The method of claim 12 , wherein said powder composition is administered at a frequency of one or two times daily.
29. The capsule of claim 1 , wherein the capsule shell is hydroxypropylmethyl cellulose (HPMC).